Abstract
Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel.
Methods: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.
Results: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.
Conclusion: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
Keywords: Acute coronary syndrome, clinical efficacy, clopidogrel besylate, coronary artery disease, generic clopidogrel, peripheral artery disease, stroke.
Current Vascular Pharmacology
Title:Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Volume: 13 Issue: 6
Author(s): Kyriafina Terzoudi, Spiros Konstantinou, Haralampos Milionis, Adamantios Bourdakis, Dimitrios Nikolopoulos, Leonidas Peltekis, Nikos Prokopakis, Ioannis Sinteles, Christos S. Stroumbis, Nikolaos Kipouridis, Karmelos Tsilias, Ioannis Xaraktsis, Christos Charmpas, Georgios Hatziathanasiou, Zacharias Christogiannis, Demosthenes B. Panagiotakos, John A. Goudevenos, Alexandros D. Tselepis, Ioannis Giatrakos, Kalliroi I. Kalantzi, Maria E. Tsoumani, John N. Vakalis, Vasileios Vasilakopoulos, Konstantinos Vardakis, Konstantinos N. Vemmos, Maria Voukelatou, Georgios Giannakoulas, Ioannis V. Ntalas, Vasileios Giogiakas, Georgios Goumas, Nikos Dimoulis, Antonios Draganigos, Ioannis Efthimiadis, Maria Thoma and Evangelos Kazakos
Affiliation:
Keywords: Acute coronary syndrome, clinical efficacy, clopidogrel besylate, coronary artery disease, generic clopidogrel, peripheral artery disease, stroke.
Abstract: Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel.
Methods: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.
Results: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.
Conclusion: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
Export Options
About this article
Cite this article as:
Terzoudi Kyriafina, Konstantinou Spiros, Milionis Haralampos, Bourdakis Adamantios, Nikolopoulos Dimitrios, Peltekis Leonidas, Prokopakis Nikos, Sinteles Ioannis, Stroumbis S. Christos, Kipouridis Nikolaos, Tsilias Karmelos, Xaraktsis Ioannis, Charmpas Christos, Hatziathanasiou Georgios, Christogiannis Zacharias, Panagiotakos B. Demosthenes, Goudevenos A. John, Tselepis D. Alexandros, Giatrakos Ioannis, Kalantzi I. Kalliroi, Tsoumani E. Maria, Vakalis N. John, Vasilakopoulos Vasileios, Vardakis Konstantinos, Vemmos N. Konstantinos, Voukelatou Maria, Giannakoulas Georgios, Ntalas V. Ioannis, Giogiakas Vasileios, Goumas Georgios, Dimoulis Nikos, Draganigos Antonios, Efthimiadis Ioannis, Thoma Maria and Kazakos Evangelos, Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150316220515
DOI https://dx.doi.org/10.2174/1570161113666150316220515 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Editorial: Pharmacological Therapy to Prevent Sudden Cardiac Death: Indications and Limitations in the Era of Devices
Mini-Reviews in Medicinal Chemistry Heart Failure in the Middle East
Current Cardiology Reviews Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Cardiac Oxidative Stress and Inflammation are Similar in SAMP8 and SAMR1 Mice and Unaltered by Curcumin and Ginkgo biloba Extract Intake
Current Pharmaceutical Biotechnology Interaction of the Heart and Lungs During Exercise: Physiology and Pathophysiology in Children with Congenital Heart Disease
Current Respiratory Medicine Reviews Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions
Current Topics in Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets The Challenges of RSV Vaccines. Where do we Stand?
Recent Patents on Anti-Infective Drug Discovery Synthesis of New 1-Substituted-1H-1,2,3,4-Tetrazoles from L-α-Amino Acids and Their Biological Assays
Letters in Organic Chemistry Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Child Abuse and Neglect and its Psycho-Physical and Social Consequences: A Review of the Literature
Current Pediatric Reviews Epidemics of Obesity and Metabolic Disorders: Are Dietary Fats or Sugars Involved?
Current Nutrition & Food Science Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Nutrigenomics and Personalized Diet: What are the Anticipated Impacts for Research on Chronic Diseases and Public Health?
Current Pharmacogenomics and Personalized Medicine The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry